- Home
- JAZZ vs GWRE Comparison
JAZZ vs GWRE Comparison
Compare JAZZ & GWRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | GWRE |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.9B |
| IPO Year | 2007 | 2011 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | GWRE |
|---|---|---|
| Price | $189.20 | $145.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 14 |
| Target Price | $211.25 | ★ $257.08 |
| AVG Volume (30 Days) | 920.6K | ★ 1.7M |
| Earning Date | 05-15-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1257.14 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $1,618,693,000.00 | $719,514,000.00 |
| Revenue This Year | $7.60 | $19.92 |
| Revenue Next Year | $8.34 | $15.46 |
| P/E Ratio | ★ N/A | $377.47 |
| Revenue Growth | N/A | ★ 8.84 |
| 52 Week Low | $95.49 | $120.37 |
| 52 Week High | $197.47 | $272.60 |
Technical Indicators
Market Signals| Indicator | JAZZ | GWRE |
|---|---|---|
| Relative Strength Index (RSI) | 70.66 | 53.09 |
| Support Level | $159.78 | $121.13 |
| Resistance Level | N/A | $163.46 |
| Average True Range (ATR) | 5.04 | 6.55 |
| MACD | 2.69 | 3.53 |
| Stochastic Oscillator | 75.97 | 97.39 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.